Genetic testing has expanded significantly, both in clinical contexts and beyond. Understanding the distinctions between testing modalities—genotyping, targeted panels, exome sequencing, and whole genome sequencing—matters for decisions about study design, eligibility criteria, and participant qualification. The available testing modalities differ meaningfully in scope, cost, and the nature of information they generate.
This webinar, hosted by Paul Wicks featuring Craig Lipset and Liam Eves focussed on some of the major challenges of decentralized and hybrid clinical trials, solutions to overcome them, and some practical examples.
In this webinar, Patrick Short (Co-Founder and CEO at Sano Genetics) and Will Jones (Co-Founder and CTO at Sano Genetics) discuss the technical challenges of biomarker-based pre-screening. Patrick and Will touch on the importance of running large-scale clinical research programs that are focused on biomarkers, the challenges of finding a central source of truth for participant numbers, how best to ensure compliance across different jurisdictions, and how to engage participants in long-term programs.
In this blog we explore the impact of COVID-19 on clinical trial recruitment, the role of patient-centricity in creating long-term engagement and more.
Patient experience is far more than a performance metric. It is a structural factor that shapes enrollment, retention, and the long-term quality of clinical research. Understanding what it means, and how to measure and improve it, is essential for teams designing studies that depend on sustained participant engagement.
- Sano raises $11 million in Series A funding round led by MMC Ventures
- New funding will support the team to grow and further its mission to accelerate personalised medicine research
- Sano aims to address the challenge of a decades-long, costly drug development process so that new treatments can reach patients faster
In this blog we explore the impact of the COVID-19 pandemic on clinical trials, how organisation have been rethinking current approaches, and what the future of virtual clinical trials could look like.
- Sano Genetics supports personalised medicine research by increasing participation in clinical trials and guiding patients through the process
- Half of clinical trials are delayed due to recruitment issues and 85% fail as they can’t retain enough participants
- Seed round will fund free at-home DNA testing kits for 3,000 people affected by Long Covid, further development of its tech platform and team expansion
If you missed our webinar, you can catch up on an exciting discussion about the future of precision medicine research in multiple sclerosis here on our blog.
Advances in large-scale genome sequencing, data storage, and analysis are accelerating the development of precision medicine across a growing number of therapeutic areas. These advancements are already helping to improve outcomes for patients with chronic diseases such as coronary artery disease and breast cancer. Depression, however, presents a distinct challenge.